Samsung Ushers in a New Era of Diagnostic Solutions at RSNA 2023

Samsung will feature the latest innovation in cutting-edge mobile computed tomography, including the state-of-the-art OmniTom Elite with Photon Counting Detector (PCD) technology

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd. and a pioneer in premium diagnostic imaging solutions, will showcase its latest offerings in mobile computed tomography (CT) and feature the OmniTom® Elite Photon Counting mobile CT scanner at the Radiological Society of North America (RSNA) Annual Meeting in Chicago from November 26 to November 30.

The clinical launch of the OmniTom Elite with PCD, the first US FDA 510(k) cleared single-source photon counting computed tomography scanner with a single detector on a mobile system, will be featured at this year’s meeting. Photon counting is a next-generation CT technology that sorts the different energies of X-rays after they have passed through the scan field, capturing the X-ray photons directly at the detector and converting the energy to electrical signals.

The OmniTom Elite’s ability to provide versatile, real-time mobile imaging enables healthcare providers to administer point-of-care CT to critical patients without the need to transport them to a separate department, expanding the diagnostic possibilities of CT at the patient’s bedside.

Upgrading capabilities were top of mind when designing OmniTom Elite mobile CT scanners. In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with the PCD technology. Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.

The University of Dundee has partnered with NeuroLogica to collaborate on research aimed at pushing the boundaries of medical imaging in healthcare.

“With NeuroLogica’s new, emerging technologies, we are currently witnessing the biggest innovation in imaging in the last decade,” said Professor Iris Grunwald, Chair of Neuroradiology at The University of Dundee.

This has allowed NeuroLogica to build on design features from the first US FDA US 510(k) clearance in 2022 to the second one in June 2023, to include high resolution mode scanning and multi-energy CT functionality with spectral capability for material decomposition and virtual monoenergetic images (VMI).*

“The OmniTom Elite is an advanced imaging solution that is extremely mobile, giving healthcare providers more flexibility in when and where they run diagnostic tests for their patients,” said Renaud Maloberti, Head of Business, MCT. “We look forward to featuring this innovative technology at this year’s Radiological Society of North America Annual Meeting.”

Massachusetts General Hospital is also collaborating with NeuroLogica and testing the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

“Availability of photon-counting detector technology on a mobile head CT platform is a significant advance in the development of CT,” said Rajiv Gupta, PhD, MD, Neuroradiology Division Chief of Massachusetts General Hospital and Associate Professor at Harvard Medical School. “This advance heralds a new era of CT applications in stroke, trauma, ICU and intra-op settings.”

NeuroLogica will showcase its innovation at Booth #6113, McCormick Place, and unveil the OmniTom Elite with PCD on Sunday, November 26 at 10:30 am CST, with a live demonstration of this state-of-the-art technology.

Also on Sunday, November 26 from 11:45 am to 12:45 pm CST in the South Building, Level 4, Room S403B, McCormick Place, Dr. Rajiv Gupta of Massachusetts General Hospital and Professor Iris Grunwald of the University of Dundee will host the Samsung NeuroLogica Lunch & Learn Event “Photon Counting: The Next Generation of Neuro CT.” They will discuss how leveraging the latest innovation in CT applications may increase productivity and enhance the patient and physician experience.

For more information or to register, visit www.eventcreate.com/e/samsungrsna2023.

*OmniTom Elite with PCD may not be commercially available in some countries. OmniTom Elite with PCD is only supported for adult axial imaging for head and neck.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version